Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon in Infants with Congenital Hyperinsulinism
NCT04172441Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Jun 2020
- Primary completion
- Feb 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
A Phase 3 trial of dasiglucagon in congenital hyperinsulinism (HI), sponsored by Zealand Pharma. Started Jun 2020; status: completed.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT04172441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172441.